Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
1.01
Dollar change
-0.01
Percentage change
-0.98
%
IndexRUT P/E- EPS (ttm)-0.13 Insider Own0.44% Shs Outstand188.82M Perf Week13.10%
Market Cap190.71M Forward P/E- EPS next Y-0.17 Insider Trans- Shs Float188.00M Perf Month4.33%
Income-23.66M PEG- EPS next Q-0.04 Inst Own50.48% Short Float6.87% Perf Quarter-28.37%
Sales8.00M P/S23.84 EPS this Y8.33% Inst Trans0.01% Short Ratio12.66 Perf Half Y-15.83%
Book/sh0.38 P/B2.63 EPS next Y-56.36% ROA-21.34% Short Interest12.92M Perf Year-27.34%
Cash/sh0.23 P/C4.37 EPS next 5Y- ROE-33.12% 52W Range0.84 - 1.61 Perf YTD-7.34%
Dividend Est.- P/FCF- EPS past 5Y19.25% ROI-31.73% 52W High-37.27% Beta1.30
Dividend TTM- Quick Ratio2.71 Sales past 5Y119.78% Gross Margin83.18% 52W Low20.64% ATR (14)0.06
Dividend Ex-Date- Current Ratio2.71 EPS Y/Y TTM2.88% Oper. Margin-309.28% RSI (14)56.13 Volatility5.72% 5.93%
Employees75 Debt/Eq0.04 Sales Y/Y TTM-32.48% Profit Margin-295.59% Recom1.50 Target Price5.20
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q-39.30% Payout- Rel Volume0.46 Prev Close1.02
Sales Surprise6.22% EPS Surprise-4.44% Sales Q/Q-39.48% EarningsMay 09 AMC Avg Volume1.02M Price1.01
SMA208.54% SMA500.48% SMA200-8.64% Trades Volume474,164 Change-0.98%
Date Action Analyst Rating Change Price Target Change
Nov-02-22Initiated Robert W. Baird Outperform $5
Jun-14-22Initiated B. Riley Securities Buy $4
Aug-19-21Initiated Noble Capital Markets Outperform $8
Mar-31-21Initiated Cantor Fitzgerald Overweight $6
Jul-02-24 08:00AM
May-30-24 08:00AM
May-21-24 08:00AM
May-10-24 04:40PM
03:49PM
02:09PM Loading…
02:09PM
May-09-24 04:01PM
May-06-24 08:00AM
May-02-24 08:00AM
Apr-30-24 08:00AM
Apr-29-24 04:30PM
Apr-19-24 12:13PM
Apr-01-24 08:00AM
Mar-18-24 10:31AM
08:00AM
03:53PM Loading…
Mar-14-24 03:53PM
Mar-13-24 08:00AM
Mar-11-24 08:00AM
Mar-08-24 04:20PM
Mar-07-24 10:36PM
04:01PM
Feb-29-24 08:00AM
Feb-13-24 08:00AM
Feb-09-24 09:15AM
Feb-06-24 09:15AM
Jan-16-24 08:00AM
Dec-18-23 08:00AM
Nov-11-23 04:02PM
Nov-10-23 02:13PM
09:17AM
04:01PM Loading…
Nov-09-23 04:01PM
Nov-01-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 05:14PM
Oct-11-23 08:00AM
Oct-05-23 08:00AM
Sep-19-23 08:00AM
Sep-13-23 08:00AM
Sep-11-23 08:00AM
Sep-06-23 09:40AM
08:00AM
Aug-29-23 08:00AM
Aug-13-23 06:39AM
Aug-11-23 09:43AM
Aug-10-23 05:15PM
04:01PM
Aug-09-23 08:50AM
Aug-08-23 06:40PM
Aug-03-23 08:00AM
Jul-24-23 08:00AM
May-22-23 08:00AM
May-16-23 12:02PM
May-11-23 05:35PM
04:01PM
May-09-23 08:00AM
May-04-23 06:15PM
08:00AM
Apr-26-23 08:00AM
Apr-18-23 08:00AM
Apr-10-23 07:57PM
Mar-30-23 08:00AM
Mar-28-23 03:57PM
Mar-20-23 08:00AM
Mar-11-23 03:00AM
Mar-10-23 06:33AM
Mar-09-23 05:25PM
04:01PM
Mar-06-23 08:00AM
Mar-02-23 09:55AM
08:00AM
Feb-22-23 09:46AM
08:00AM
Feb-08-23 08:00AM
Nov-29-22 08:00AM
Nov-28-22 08:00AM
Nov-17-22 12:00PM
09:45AM
Nov-10-22 06:35PM
04:05PM
Nov-08-22 05:45PM
Nov-03-22 08:00AM
Oct-31-22 08:00AM
Oct-10-22 08:00AM
Oct-04-22 08:00AM
Oct-03-22 08:00AM
07:41AM
Sep-19-22 07:00AM
Aug-15-22 08:00AM
Aug-12-22 09:30AM
02:31AM
Aug-11-22 04:05PM
Aug-08-22 06:05PM
Aug-04-22 08:00AM
Jul-14-22 08:45AM
Jun-02-22 08:00AM
May-16-22 10:25AM
May-12-22 06:05PM
04:05PM
May-11-22 05:55PM
May-10-22 10:15AM
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Culley Brian MPresident and CEOMay 24 '24Buy1.0510,00010,500154,842May 28 09:11 AM
BAILEY DON MDirectorFeb 08 '24Buy1.0496,155100,001158,801Feb 08 07:00 PM
BROADWOOD PARTNERS, L.P.DirectorFeb 06 '24Buy1.046,730,7707,000,00141,666,255Feb 08 06:58 PM
Jayasuriya AnulaDirectorDec 29 '23Buy1.0910,00010,90010,000Jan 02 07:08 PM